INDV 6-K
Indivior Pharmaceuticals, Inc. (INDV)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
________________________
Washington, D.C. 20549
_____________________
FORM 6-K
_____________________
Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16
under the Securities Exchange Act of 1934
For the month of October 2024
Commission File Number: 001-37835
________________________________________
Indivior PLC
________________________________________
10710 Midlothian Turnpike, Suite 125
North Chesterfield, Virginia 23235
(Address of principal executive office)
_______________________________
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F
Form 20-F ☒ Form 40-F ☐
EXHIBIT INDEX
| Exhibit<br>No. | Description<br>of Exhibit |
|---|---|
| 99.1 | Announcement sent to the London Stock Exchange on October 03, 2024,<br>titled “Chair Succession Plan”. |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| Indivior PLC | |
|---|---|
| Date: October 03, 2024 | /s/<br>Kathryn Hudson |
| Name:<br>Kathryn Hudson | |
| Title:<br>Company Secretary |
a8751g
Exhibit 99.1
INDIVIOR PLC
CHAIR SUCCESSION PLAN
Richmond, VA, and Slough, UK, October 3, 2024 - Indivior PLC (Nasdaq/LSE: INDV) today announces that Graham Hetherington has informed the Board of his intention to retire as Chair and from the Board at the end of 2024 for personal reasons. Graham has been a member of the Board for five years, including four years as Chair of the Board.
The Nomination Committee, led by the Senior Independent Director, Juliet Thompson, has commenced a comprehensive search process to identify Graham's successor.
The Board would like to express its sincere thanks to Graham for his significant contribution to Indivior since joining the Board in 2019.
Graham Hetherington commented:
"It has been a privilege to serve as Chair of Indivior, working closely with an outstanding Board and highly dedicated management team who have an unwavering commitment to develop life-transforming treatments for patients suffering from substance use disorders, serious mental illness and overdose."
Key Contacts:
Jason Thompson
VP, Investor Relations
+1 804-402-7123 or [email protected]
Tim Owens
Director, Investor Relations
+1 804-263-3978 or [email protected]
About Indivior
Indivior is a global pharmaceutical company working to help change patients' lives by developing medicines to treat substance use disorders (SUD), overdose and serious mental illnesses. Our vision is that all patients around the world will have access to evidence-based treatment for the chronic conditions and co-occurring disorders of SUD. Indivior is dedicated to transforming SUD from a global human crisis to a recognized and treated chronic disease.
Building on its global portfolio of OUD treatments, Indivior has a pipeline of product candidates designed to both expand on its heritage in this category and potentially address other chronic conditions and co-occurring disorders of SUD. Headquartered in the United States in Richmond, VA, Indivior employs over 1,000 individuals globally and its portfolio of products is available in over 30 countries worldwide. Visit www.indivior.com to learn more. Connect with Indivior on LinkedIn by visiting www.linkedin.com/company/indivior.